X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

APVO

Closed

Aptevo Therapeutics Inc

2.95
-0.10 (-3.28%)
Last Update: 01 Jul 2025 23:01:00
Yesterday: 3.05
Day's Range: 2.9451 - 3.1856
Send
When Written:
 
2.035
Aptevo Therapeutics Inc is a biotechnology company that focuses on the development of novel immunotherapies for the treatment of cancer and other diseases. The company was founded in 2016 as a spin-off from Emergent BioSolutions Inc.

Aptevo's lead product candidate is APVO436, a bispecific antibody that targets CD123 and CD3, which is being developed for the treatment of acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing a pipeline of other bispecific antibodies, as well as antibody-drug conjugates (ADCs) and other immunotherapies.

In addition to its oncology programs, Aptevo has a portfolio of products for the treatment of hemophilia and other bleeding disorders, including IXINITY, a recombinant factor IX therapy, and WinRho SDF, an intravenous immunoglobulin product.

Aptevo is headquartered in Seattle, Washington, and has a research and development facility in San Diego, California. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol APVO.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X